CN113861047B - 一种2-(2-甲氧基苯氧基)乙胺的合成方法 - Google Patents
一种2-(2-甲氧基苯氧基)乙胺的合成方法 Download PDFInfo
- Publication number
- CN113861047B CN113861047B CN202111097135.0A CN202111097135A CN113861047B CN 113861047 B CN113861047 B CN 113861047B CN 202111097135 A CN202111097135 A CN 202111097135A CN 113861047 B CN113861047 B CN 113861047B
- Authority
- CN
- China
- Prior art keywords
- methoxyphenoxy
- ethylamine
- synthesis method
- guaiacol
- ethanolamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- CKJRKLKVCHMWLV-UHFFFAOYSA-N 2-(2-methoxyphenoxy)ethanamine Chemical compound COC1=CC=CC=C1OCCN CKJRKLKVCHMWLV-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 238000001308 synthesis method Methods 0.000 title claims abstract description 13
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 claims abstract description 34
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims abstract description 26
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960001867 guaiacol Drugs 0.000 claims abstract description 17
- 239000004202 carbamide Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 12
- 238000006243 chemical reaction Methods 0.000 claims abstract description 11
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 27
- 238000010438 heat treatment Methods 0.000 claims description 14
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 7
- 238000004321 preservation Methods 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 3
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 239000003513 alkali Substances 0.000 abstract description 2
- 238000006555 catalytic reaction Methods 0.000 abstract description 2
- 238000005580 one pot reaction Methods 0.000 abstract description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CJHKWIFDLHQWCU-UHFFFAOYSA-N 1-(2-chloroethoxy)-2-methoxybenzene Chemical compound COC1=CC=CC=C1OCCCl CJHKWIFDLHQWCU-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 2
- 229960004195 carvedilol Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- NGZBCWWJDDVXAQ-UHFFFAOYSA-N 2-(2-methoxyphenoxy)ethanol Chemical compound COC1=CC=CC=C1OCCO NGZBCWWJDDVXAQ-UHFFFAOYSA-N 0.000 description 1
- WRBSZMMWHCAUKD-UHFFFAOYSA-N 2-[2-(2-methoxyphenoxy)ethyl]isoindole-1,3-dione Chemical compound COC1=CC=CC=C1OCCN1C(=O)C2=CC=CC=C2C1=O WRBSZMMWHCAUKD-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/06—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton from hydroxy amines by reactions involving the etherification or esterification of hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明提供了一种2‑(2‑甲氧基苯氧基)乙胺的合成方法,属于有机合成技术领域。本发明以愈创木酚、尿素和乙醇胺为起始原料,通过“一锅法”完成三步反应合成2‑(2‑甲氧基苯氧基)乙胺。提供了一种全新的2‑(2‑甲氧基苯氧基)乙胺合成思路,创新地避免直接使用价格昂贵的2‑恶唑烷酮,利用尿素和乙醇胺合成2‑恶唑烷酮,再以碱的催化下直接与愈创木酚反应生成2‑(2‑甲氧基苯氧基)乙胺。
Description
技术领域
本发明属于有机合成技术领域,具体涉及一种2-(2-甲氧基苯氧基)乙胺的合成方法。
背景技术
2-(2-甲氧基苯氧基)乙胺是合成β-受体阻断剂卡维地洛的一个重要中间体,卡维地洛是一种治疗原发性高血压的药,可单独使用或与其它抗高血压药特别是噻嗪类利尿剂联合使用,卡维地洛也可用于治疗有症状的充血性心力衰竭可降低死亡率和心血管事件的住院率,改善病人一般情况并减慢疾病进展。现有技术中针对2-(2-甲氧基苯氧基)乙胺的合成方法具有多种,但是存在收率低、成本高的情况。
例如,专利WO2009128088A2公开了2-(2-甲氧基苯氧基)乙胺的制备方法,首先愈创木酚和1,2-二氯乙烷反应得到1-(2-氯乙氧基)-2-甲氧基苯,再通过Gabriel反应获得2-(2-甲氧基苯氧基)乙胺。该合成线路较长,三步总收率不到43%,使用邻苯二甲酰亚胺钾价格高,生产成本较高。
再如,专利CN109206328A公开了一种合成路线:以愈创木酚为起始原料合成2-(2-甲氧基苯氧基)乙醇,经氯代合成2-(2-甲氧基苯氧基)氯乙烷,然后与邻苯二甲酰亚胺钾盐反应得到N-(邻甲氧基苯氧乙基)-邻苯二甲酰亚胺,最后经碱水解得到2-(2-甲氧基苯氧基)乙胺。该路线较长,操作繁琐,使用二氯亚砜试剂容易腐蚀反应设备,不利于工业化生产。
综上,现有合成2-(2-甲氧基苯氧基)乙胺的方法还存在反应路线长、操作繁琐、反应试剂价格昂贵、工艺条件苛刻,不利于工业化的缺点,并且生产成本高。
发明内容
基于现有技术中存在的缺陷和不足,本发明提供了一种2-(2-甲氧基苯氧基)乙胺的合成方法,具有原料廉价、路线短、收率高和反应操作简单的优势。
为实现上述目的,本发明提供的一种2-(2-甲氧基苯氧基)乙胺的合成方法,包括以下步骤:
将愈创木酚、尿素、乙醇胺和氢氧化钾加入反应容器中,加热后保温,加乙二胺,保温后冷却,溶解、洗涤、萃取后浓缩得棕黑色液体,即为2-(2-甲氧基苯氧基)乙胺。
所述的反应的反应方程式为:
其中,所述的愈创木酚、尿素、乙醇胺和氢氧化钾的摩尔比为1:1-2:1-2:0.05-0.5。
优选地,所述的愈创木酚、尿素、乙醇胺和氢氧化钾的摩尔比为1:1.6:1.6:0.1。
所述的加热保温温度为170℃,升温速度为每小时升温10℃。
所述的乙二胺加入量为愈创木酚摩尔量的50%;
第一次保温的时间为6-20h;优选为6h、15h或20h。
第二次保温的时间为2h。
上述反应可在有溶剂或无溶剂的条件下进行,所述溶剂为均三甲苯或N-甲基吡咯烷酮。
现有技术相比,本发明的有益效果:
本发明以愈创木酚、尿素和乙醇胺为起始原料,通过“一锅法”完成三步反应合成2-(2-甲氧基苯氧基)乙胺。提供了一种全新的2-(2-甲氧基苯氧基)乙胺合成思路,创新地避免直接使用价格昂贵的2-恶唑烷酮,利用尿素和乙醇胺合成2-恶唑烷酮,再以碱的催化下直接与愈创木酚反应生成2-(2-甲氧基苯氧基)乙胺。
附图说明
图1为本发明实施例制备的2-(2-甲氧基苯氧基)乙胺核磁图谱;
具体实施方式
本发明中提到的上述特征,或实施例提到的特征可以任意组合。本案说明书所解释的所有特征可与任意方法形式并用,说明书中揭示的各个特征,可被任何可提供相同、均等或相似目的的取代性特征取代。因此除有特殊说明,所揭示的特征仅为均等或相似特征的一般性例子。
下面结合具体实施例,进一步阐述本发明。这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中为注明具体条件的实施方法,通常按照常规条件或按照制造厂商所建议的条件。除非特殊说明,否则所有的百分比和分数按重量计。
除非另行定义,文中所使用的所有专业与科学用语与本领域技术人员所熟知的意义相同。此外,任何与所记载内容相似或均等的方法及材料皆可应用于本发明方法中。文中所述的优选实施方法与材料仅做示范作用。
实施例1
2-(2-甲氧基苯氧基)乙胺的制备:
向250ml单口瓶中加入愈创木酚(12.41g,0.1mol),尿素(9.60g,0.16mol),乙醇胺(9.76g,0.16mol)和氢氧化钾(2.80g,0.05mol),120℃加热,程序升温至170℃(每半小时升温10℃),保温6h,加乙二胺(3.00g,0.05mol),在170℃条件下继续加热2h,冷却后向反应产物加50ml水溶解,浓盐酸调pH=2,过滤,水层加50ml氯仿洗涤一次,20%氢氧化钠溶液调pH=13,加50ml氯仿萃取,减压蒸出氯仿,得棕黑色液体11.4g,GC检测纯度52.9%,收率36.1%。
实施例2
2-(2-甲氧基苯氧基)乙胺的制备:
向250ml单口瓶中加入愈创木酚(12.41g,0.1mol),尿素(9.60g,0.16mol),乙醇胺(9.76g,0.16mol),氢氧化钾(0.56g,0.01mol),加50ml均三甲苯溶解,120℃加热,程序升温至170℃(每小时升温10℃),保温15小时,加乙二胺(3.00g,0.05mol),170℃加热2h,冷却后向反应产物加50ml水溶解,浓盐酸调pH=2,过滤,水层加50ml氯仿洗涤一次,20%氢氧化钠溶液调pH=13,加50ml氯仿萃取,减压蒸出氯仿,得棕黑色液体12.7g,纯度97.0%,收率73.4%。
实施例3
2-(2-甲氧基苯氧基)乙胺的制备:
向250ml单口瓶中加入30ml均三甲苯,愈创木酚(12.41g,0.1mol),尿素(9.60g,0.16mol),乙醇胺(9.76g,0.16mol)和氢氧化钾(0.56g,0.01mol),120℃加热,程序升温至170℃(每半小时升温10℃),保温20h,加乙二胺(3.00g,0.05mol),170℃加热2h,冷却后向反应产物加50ml水溶解,浓盐酸调pH=2,过滤,水层加50ml氯仿洗涤一次,20%氢氧化钠溶液调pH=13,加50ml氯仿萃取,减压蒸出氯仿,得棕黑色液体11.6g,GC检测纯度87.3%,收率60.1%。
Claims (7)
1.一种2-( 2-甲氧基苯氧基)乙胺的合成方法,其特征在于:包括以下步骤:
将愈创木酚、尿素、乙醇胺和氢氧化钾加入反应容器中,加热后第一次保温,加乙二胺,第二次保温后冷却,溶解、洗涤、萃取后浓缩得棕黑色液体,即为2-( 2-甲氧基苯氧基)乙胺;反应在有溶剂的条件下进行,所述溶剂为均三甲苯;所述的愈创木酚、尿素、乙醇胺和氢氧化钾的摩尔比为1:1-2:1-2:0.05-0.5;所述第一次保温的时间为6-20h。
2.根据权利要求1所述的合成方法,其特征在于:所述的愈创木酚、尿素、乙醇胺和氢氧化钾的摩尔比为1:1.6:1.6:0.1。
3.根据权利要求1所述的合成方法,其特征在于:所述的加热保温的温度为170℃。
4.根据权利要求1所述的合成方法,其特征在于:所述的加热保温的升温速度为每小时升温10℃。
5.根据权利要求1所述的合成方法,其特征在于:所述的乙二胺加入量为愈创木酚摩尔量的50%。
6.根据权利要求1所述的合成方法,其特征在于:第一次保温的时间6h、15h或20h。
7.根据权利要求1所述的合成方法,其特征在于:第二次保温的时间为2h。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111097135.0A CN113861047B (zh) | 2021-09-18 | 2021-09-18 | 一种2-(2-甲氧基苯氧基)乙胺的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111097135.0A CN113861047B (zh) | 2021-09-18 | 2021-09-18 | 一种2-(2-甲氧基苯氧基)乙胺的合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113861047A CN113861047A (zh) | 2021-12-31 |
CN113861047B true CN113861047B (zh) | 2024-05-14 |
Family
ID=78992629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111097135.0A Active CN113861047B (zh) | 2021-09-18 | 2021-09-18 | 一种2-(2-甲氧基苯氧基)乙胺的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113861047B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101066930A (zh) * | 2007-06-12 | 2007-11-07 | 中国药科大学 | 2-[2-(2,2,2-三氟乙氧基)]苯氧基乙胺的制备方法 |
JP2014062071A (ja) * | 2012-09-21 | 2014-04-10 | Showa Denko Kk | エチレン性不飽和基含有イソシアネート化合物の製造方法 |
CN109206328A (zh) * | 2018-09-27 | 2019-01-15 | 铜仁学院 | 一种2-(2-甲氧基苯氧基)乙胺的制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9035097B2 (en) * | 2012-09-12 | 2015-05-19 | Chevron Oronite Company Llc | Aminoethylation process having improved yield of aryloxyalkylene amine compounds and reduced urea by-products |
-
2021
- 2021-09-18 CN CN202111097135.0A patent/CN113861047B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101066930A (zh) * | 2007-06-12 | 2007-11-07 | 中国药科大学 | 2-[2-(2,2,2-三氟乙氧基)]苯氧基乙胺的制备方法 |
JP2014062071A (ja) * | 2012-09-21 | 2014-04-10 | Showa Denko Kk | エチレン性不飽和基含有イソシアネート化合物の製造方法 |
CN109206328A (zh) * | 2018-09-27 | 2019-01-15 | 铜仁学院 | 一种2-(2-甲氧基苯氧基)乙胺的制备方法 |
Non-Patent Citations (3)
Title |
---|
2-( 2-甲氧基苯氧基) 乙胺的制备;彭震云;《中国医药工业杂志》;第34卷(第11期);548 * |
Non-catalytic clean synthesis route using urea to cyclic urea and cyclic urethane compounds;Bhalchandra M. Bhanage et al.;《Green Chemistry》;第6卷(第2期);78-80 * |
张金玉等.《有机合成反应及路线设计研究》.中国原子能出版社,2021,(第2021年5月第1版),253. * |
Also Published As
Publication number | Publication date |
---|---|
CN113861047A (zh) | 2021-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104086379B (zh) | 达格列净中间体的合成方法 | |
WO2017096772A1 (zh) | 一种抗心衰药lcz696的制备方法 | |
CN109503513B (zh) | 一种非布司他中间体的“一锅法”合成方法 | |
CN110790721A (zh) | 头孢他啶侧链酸乙酯的合成方法 | |
CN101274888B (zh) | 一种双或多甲氧基取代苯乙酸的制备方法 | |
CN113861047B (zh) | 一种2-(2-甲氧基苯氧基)乙胺的合成方法 | |
CN105085362A (zh) | 高纯度结晶型阿托伐他汀钙的制备方法 | |
CN102140084A (zh) | 一种曲美他嗪及其盐酸盐的生产方法 | |
CN114736154B (zh) | N-(3-氯-4-(2-吡啶甲氧基)苯基)-2-氰基乙酰胺的制备方法 | |
CN108329218B (zh) | 一种(r)-肾上腺素的制备方法 | |
CN112174871A (zh) | 制备吲哚啉的方法 | |
CN110563643A (zh) | 一种(5-溴-3-甲基-吡啶-2-基)-甲胺的合成方法 | |
CN111393432A (zh) | 去甲托品醇盐析制备方法 | |
CN102391170B (zh) | 一种n,n-二烯丙基-5-甲氧基色胺盐酸盐的制备方法 | |
CN112225736B (zh) | 一种6-溴咪唑并[1.2-a]吡啶-3-甲醛的制备方法 | |
CN101723879B (zh) | 一种合成(r)-3-哌啶乙酸乙酯盐酸盐的方法 | |
CN101492388A (zh) | 一种合成米曲肼药物原料的方法 | |
CN100554252C (zh) | 一种琥珀酸舒马曲坦的制备方法 | |
CN109879775A (zh) | 一种5-氨基乙酰丙酸盐酸盐中间体的环保制备方法 | |
CN114195684B (zh) | 一种氨基保护基n-取代手性氨基酸的合成方法 | |
CN116589341A (zh) | 一种抗高血酯药物中间体的制备方法 | |
CN113861014B (zh) | 乙酰丙酸-13c及制备方法和应用 | |
CN116063163B (zh) | 7-(苄氧基)-2,4,5,6-四氢-1H-环丁二烯[f]茚-1-酮的制备方法 | |
CN114163362B (zh) | 一种n-苯磺酰基-4-卤-2-硝基苯胺制备方法 | |
JPH10218847A (ja) | タートラニル酸の製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |